Licensing status

Publication and contact information

Assays & screens

Tumor endothelial marker (TEM)-expressing circulating endothelial cells (CECs) as a blood-based marker to detect tumors and monitor response to antiangiogenic therapy

Studies in human samples and mice suggest TEM+ CECs could help detect the presence of tumors and monitor tumor response to antiangiogenic therapy. Mice with human non-small cell lung cancer (NSCLC) xenografts had higher numbers of plexin domain containing 1 (PLXDC1; TEM7)+ CECs in blood than mice without xenografts. In the mouse xenograft model, antiangiogenic drugs decreased the number of TEM7+ CECs in blood compared with vehicle. In patients undergoing tumor resection, TEM+ CEC numbers in blood samples taken after surgery were lower than those in samples taken before resection. Next steps could include assessing TEM+ CEC numbers in a larger patient cohort.

SciBX 7(15); doi:10.1038/scibx.2014.439
Published online April 17, 2014

Patent and licensing status unavailable

Mehran, R. et al. Cancer Res.; published online March 13, 2014;
Contact: John V. Heymach, The University of Texas MD Anderson Cancer Center, Houston, Texas